Mizuho reiterates Arm Holdings stock rating on AI chip roadmap By Investing.com

Arm guided fiscal 2031 revenues to $25.0B and targeted EPS above $9 (vs fiscal 2026 consensus ~$1.75), disclosed the AGI CPU launching in H2 2026 with first revenues ~ $1B in fiscal 2028, and said the product addresses a TAM of $50B today rising to >$100B by 2030. Analysts reacted by lifting price targets (Guggenheim $240, Evercore $227, Mizuho $160, RBC $175, Raymond James $166; BofA $140 Neutral), reflecting optimism about Arm’s strategic shift from IP licensing to fabless full-chip production despite ramp NRE of ~$200M/quarter and aggressive long-term assumptions.

Analysis

Arm’s strategic move into finished silicon shifts value capture downstream and forces a re-pricing of who gets the bulk of datacenter economics. If Arm executes, hyperscalers can redeploy recurring licensing spend into a mix of chip purchases and services, compressing incumbent CPU vendors’ gross margin pools and increasing bargaining leverage for foundries and system integrators.

The most important second-order supply-chain effect is foundry capacity and tooling cadence: a meaningful merchant CPU ramp by Arm will front-load high-margin wafer demand at leading-node fabs and amplify demand for advanced packaging and power-delivery components, tightening lead times for other GPU/CPU suppliers. Software and systems-level integration (kernel, compiler, orchestration) becomes the gating factor — performance claims without a mature stack will slow customer-scale adoption even if raw silicon is competitive.

Key risks are execution/timing and concentration: a product that under-performs in independent benchmarks, or a hiccup in yield/partner foundry commitments, would flip the narrative quickly. Watch catalysts on 6–24 month horizons — independent performance data, foundry supply agreements, and large-cloud order flow — and negative catalysts like third-party benchmark misses, major customer pushback, or emergent antitrust/IP litigation that can pause deployments.

Given market enthusiasm, positioning should favor optionality: asymmetric option structures or relative-value pairs to capture upside from share gains while limiting exposure to binary execution risks. Avoid outright high-conviction long risk without hedges until we see multi-customer production traction and independent TCO validation over a 12–24 month window.

Key Decisions for Investors

• Long ARM (NASDAQ:ARM) via 18–30 month LEAP call debit spread (buy Jan-2028 LEAP calls, sell a higher-strike Jan-2028 call) sized 2–4% portfolio. R/R: limited premium paid vs uncapped upside if multi-customer ramps; hedge execution/time risk vs selling nearer-term calls to fund part of the purchase.
• Relative-value pair: Long ARM / Short INTC (or AMD) equal notional, 12–24 month horizon. R/R: isolates share-shift thesis away from market beta — if Arm takes server share, this captures spread expansion; downside if broader datacenter spend weakens or incumbents bundle competitively.
• Tactical long on hyperscaler beneficiaries (e.g., META) size 1–2% with 12–18 month call options to play lower TCO tailwinds. R/R: modest option spend buys exposure to improved FCF trajectory if customer TCO falls; risk is minimal direct upside if Arm ramp disappoints.
• Supplier play: Add exposure to leading foundry/packaging names (TSM, ASML) via 6–18 month call overlays. R/R: benefits from incremental wafer/package demand; risk is cyclical fab investment delays or allocation to priority customers.
• Capital-protective alternative: Buy out-of-the-money puts on ARM (9–12 month) equal to 25–50% of long exposure or fund long via call spreads to cap downside. R/R: preserves upside optionality while capping losses from binary execution failures or negative benchmark surprises.